Literature DB >> 33826460

Net benefit separation and the determination curve: A probabilistic framework for cost-effectiveness estimation.

Andrew J Spieker1, Nicholas Illenberger2, Jason A Roy3, Nandita Mitra2.   

Abstract

Considerations regarding clinical effectiveness and cost are essential in comparing the overall value of two treatments. There has been growing interest in methodology to integrate cost and effectiveness measures in order to inform policy and promote adequate resource allocation. The net monetary benefit aggregates information on differences in mean cost and clinical outcomes; the cost-effectiveness acceptability curve was developed to characterize the extent to which the strength of evidence regarding net monetary benefit changes with fluctuations in the willingness-to-pay threshold. Methods to derive insights from characteristics of the cost/clinical outcomes besides mean differences remain undeveloped but may also be informative. We propose a novel probabilistic measure of cost-effectiveness based on the stochastic ordering of the individual net benefit distribution under each treatment. Our approach is able to accommodate features frequently encountered in observational data including confounding and censoring, and complements the net monetary benefit in the insights it provides. We conduct a range of simulations to evaluate finite-sample performance and illustrate our proposed approach using simulated data based on a study of endometrial cancer patients.

Entities:  

Keywords:  Censoring; confounding; cost-effectiveness; observational; policy

Year:  2021        PMID: 33826460      PMCID: PMC8211369          DOI: 10.1177/0962280221995972

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  30 in total

1.  Linear regression analysis of censored medical costs.

Authors:  D Y Lin
Journal:  Biostatistics       Date:  2000-03       Impact factor: 5.899

2.  Cost-effectiveness of home versus clinic-based management of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized trial cohort - The WHICH? study (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care).

Authors:  Shoko Maru; Joshua Byrnes; Melinda J Carrington; Yih-Kai Chan; David R Thompson; Simon Stewart; Paul A Scuffham
Journal:  Int J Cardiol       Date:  2015-08-08       Impact factor: 4.164

3.  An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?

Authors:  Jason Shafrin; Michelle Skornicki; Michelle Brauer; Julie Villeneuve; Michael Lees; Nadine Hertel; John R Penrod; Jeroen Jansen
Journal:  Health Policy       Date:  2018-04-26       Impact factor: 2.980

4.  Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty.

Authors:  Andrew Briggs
Journal:  Value Health       Date:  2005 Jan-Feb       Impact factor: 5.725

5.  Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.

Authors:  A R Willan; B J O'Brien
Journal:  Health Econ       Date:  1996 Jul-Aug       Impact factor: 3.046

Review 6.  Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.

Authors:  A H Briggs; D E Wonderling; C Z Mooney
Journal:  Health Econ       Date:  1997 Jul-Aug       Impact factor: 3.046

7.  A cost-effectiveness analysis of school-based suicide prevention programmes.

Authors:  Susan Ahern; Lee-Ann Burke; Brendan McElroy; Paul Corcoran; Elaine M McMahon; Helen Keeley; Vladimir Carli; Camilla Wasserman; Christina W Hoven; Marco Sarchiapone; Alan Apter; Judit Balazs; Raphaela Banzer; Julio Bobes; Romuald Brunner; Doina Cosman; Christian Haring; Michael Kaess; Jean-Pierre Kahn; Agnes Kereszteny; Vita Postuvan; Pilar A Sáiz; Peeter Varnik; Danuta Wasserman
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-02-14       Impact factor: 4.785

8.  Nested g-computation: A causal approach to analysis of censored medical costs in the presence of time-varying treatment.

Authors:  Jason A Roy; Nandita Mitra; Andrew J Spieker; Emily M Ko
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2020-08-25       Impact factor: 1.864

9.  EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT.

Authors:  Elizabeth A Handorf; Justin E Bekelman; Daniel F Heitjan; Nandita Mitra
Journal:  Ann Appl Stat       Date:  2013       Impact factor: 2.083

10.  Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.

Authors:  Elisabeth Fenwick; Deborah A Marshall; Adrian R Levy; Graham Nichol
Journal:  BMC Health Serv Res       Date:  2006-04-19       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.